Member

Phare Bio


Phare Bio is a social venture dedicated to addressing the urgent global threat of antibiotic resistance through innovative AI and deep learning technologies. The company aims to revolutionize antibiotic discovery and development, ensuring that new antibiotics reach those in greatest need.

Industries

artificial-intelligence
biotechnology

Nr. of Employees

small (1-50)

Phare Bio


Products

Generative AI antibiotics discovery platform

A platform that applies generative deep learning and interpretable ML to design, prioritize and accelerate novel antibiotic candidates.

Expertise Areas

  • AI-driven antibiotic discovery
  • Generative deep learning model development
  • High-throughput virtual screening
  • Hit-to-lead optimization and ADME/Tox
  • Show More (8)

Key Technologies

  • Generative deep learning models
  • Deep neural networks for activity prediction
  • Explainable / interpretable machine learning
  • Large-scale virtual screening
  • Show More (6)

Key People

Akhila Kosaraju

M.D., CEO & President

LinkedIn

James J. Collins

Ph.D., Co-founder & Chair of the Scientific Advisory Board

LinkedIn

Leanne Minall

Ph.D., Director of R&D and Scientific Strategy

LinkedIn

Joseph Vacca

Ph.D., Medicinal Chemistry

LinkedIn

David Pompliano

Ph.D., Anti-Infective Strategy

LinkedIn

Magdalena Zalacain

Ph.D., Preclinical R&D

LinkedIn
View All People

News & Updates

Phare Bio has received funding to enhance its AI-driven drug discovery efforts, focusing on developing new antibiotics.

Phare Bio is a recent recipient of the ARPA-H Award, aimed at accelerating AI-powered drug discovery.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.